![](/images/graphics-bg.png)
Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
Joint Authors
Tamar, Hamburger
Vivian, Barak
Rona, Ortenberg
Tamar, Peretz
Michal, Lotem
Jacob, Schachter
Markel, Gal
Suzan, Faranesh
Sivan, Sapoznik
Source
Clinical and Developmental Immunology
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-01-16
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
The search for melanoma biomarkers is crucial, as the incidence of melanoma continues to rise.
We have previously demonstrated that serum CEACAM1 (sCEACAM1) is secreted from melanoma cells and correlates with disease progression in metastatic melanoma patients.
Here, we have used a different cohort of melanoma patients with regional or metastatic disease (N=49), treated with autologous vaccination.
By monitoring sCEACAM1 in serum samples obtained prior to and after vaccination, we show that sCEACAM1 correlates with disease state, overall survival, and S100B.
The trend of change in sCEACAM1 following vaccination (increase/decrease) inversely correlates with overall survival.
DTH skin test is used to evaluate patients’ anti-melanoma immune response and to predict response to vaccination.
Importantly, sCEACAM1 had a stronger prognostic value than that of DTH, and when sCEACAM1 decreased following treatment, this was the dominant predictor of increased survival.
Collectively, our results point out the relevance of sCEACAM1 in monitoring melanoma patients.
American Psychological Association (APA)
Sivan, Sapoznik& Suzan, Faranesh& Rona, Ortenberg& Tamar, Hamburger& Vivian, Barak& Tamar, Peretz…[et al.]. 2012. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. Clinical and Developmental Immunology،Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-460762
Modern Language Association (MLA)
Sivan, Sapoznik…[et al.]. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. Clinical and Developmental Immunology No. 2012 (2012), pp.1-8.
https://search.emarefa.net/detail/BIM-460762
American Medical Association (AMA)
Sivan, Sapoznik& Suzan, Faranesh& Rona, Ortenberg& Tamar, Hamburger& Vivian, Barak& Tamar, Peretz…[et al.]. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. Clinical and Developmental Immunology. 2012. Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-460762
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-460762